Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL28541060 | 0.93 | FFAR1 (0.49) | GRM5ASIC3FFAR1HAO1MAP3K14 | |
| SCHEMBL11443850 | 0.88 | HAO1 (0.46) | ASIC3HAO1MAP3K14EGFRMAPT | |
| SCHEMBL29116860 | 0.84 | GRM5 (0.42) | GRM5ASIC3FFAR1HAO1ACHE | |
| SCHEMBL2811570 | 0.81 | GRM5 (0.44) | GRM5ASIC3FFAR1HAO1ACHE | |
| SCHEMBL24506081 | 0.79 | HAO1 (0.41) | ASIC3HAO1MAP3K14EGFRMAPT | |
| SCHEMBL1477501 | 0.79 | KCNH2 (0.50) | GRM5ASIC3HAO1MAP3K14EGFR | |
| SCHEMBL13692775 | 0.79 | FFAR1 (0.42) | ASIC3FFAR1HAO1MAP3K14EGFR | |
| SCHEMBL30092382 | 0.79 | MAP3K14 (0.45) | ASIC3FFAR1HAO1MAP3K14EGFR | |
| SCHEMBL1795798 | 0.79 | PDK1 (0.43) | GRM5ASIC3FFAR1HAO1MAP3K14 | |
| SCHEMBL471131 | 0.79 | MAP3K14 (0.45) | ASIC3FFAR1HAO1MAP3K14EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095228-A1 | METHOD FOR THE PREPARATION OF ERLOTINIB | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095228-A1 | METHOD FOR THE PREPARATION OF ERLOTINIB | EGFR, ABL1, ERBB2 | GRM5 2904/4885ASIC3 4089/4885FFAR1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.